Better prognostic biomarkers are urgently needed to identify patients with early-stage cutaneous melanoma who will progress to aggressive disease. In the past grant period, Project II successfully developed the quantitative real-time RT-PCR assay to detect micrometastases not identified by histopathologic assessment of sentinel lymph nodes (SLN). Project II then adapted this assay for analysis of paraffin-embedded SLN specimens, and incorporated this assay as a stratification factor in the international phase III trial (MSLT-II, Project III, and Core C). In the present proposal, Project II will develop and validate clinically relevant prognostic biomarkers by undertaking genomic/epigenomic/mRNA analyses of primary tumor tissue, metastatic tumor tissue, and blood from melanoma patients accrued in the past grant period. The objective is to develop a molecular model that combines tissue-based assays and blood-based serial assays for diagnosis and prognosis. The objectives are further defined in three aims:
Aim I, Assessment of prognostic DNA biomarkers in primary melanomas of patients who have undergone SLN biopsy for melanoma.
Aim II, Identification of prognostic RNA and DNA biomarkers in nodal and distant metastases of patients who have undergone SLN biopsy for melanoma.
Aim III, Identification and assessment of prognostic circulating DNA and circulating tumor-cell biomarkers for detection of melanoma recurrence after SLN biopsy. These three Aims will take advantage of several unique resources: the clinical specimens with clinical follow-up records for patients in the two ongoing international phase III trials (MSLT-I and MSLT-II, Project Ill) and the extensive independent specimen bank/clinical database at the JWCI melanoma center. Results of these molecular biomarker studies will improve treatment selection for patients with early-stage melanoma and increase early detection of recurrent metastatic melanoma during SLN biopsy postoperative follow-up. This approach will help improve melanoma patient management and staging, especially those of early aggressive disease.

Public Health Relevance

Systemic metastasis of malignant cutaneous melanoma has a very poor prognosis which may be alleviated by early diagnosis and early detection of occult metastasis. Our objective in this proposal is to improve the molecular assessment of melanoma by developing and validating a panel of clinically relevant RNA and DNA prognostic biomarkers through assessment of primary tumors and lymph node metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA029605-32
Application #
8544987
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
32
Fiscal Year
2013
Total Cost
$641,311
Indirect Cost
$428,342
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-41
Lessard, Laurent; Liu, Michelle; Marzese, Diego M et al. (2015) The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. J Invest Dermatol 135:2464-74
Wang, Jinhua; Hua, Wei; Huang, Sharon K et al. (2015) RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget 6:30165-77
Deutsch, Gary B; Kirchoff, Daniel D; Faries, Mark B (2015) Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am 24:279-98
Faries, Mark B (2015) From the guest editor: The sentinel node: evolution of the revolution. Introduction. Cancer J 21:1-2
Marzese, Diego M; Hoon, Dave Sb (2015) Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 15:647-64
Faries, M B; Cochran, A J; Elashoff, R M et al. (2015) Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of t Br J Dermatol 172:571-3
Marzese, Diego M; Liu, Michelle; Huynh, Jamie L et al. (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28:82-93
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46

Showing the most recent 10 out of 248 publications